Repositorio
Institucional

Riffo-Campos, Angela L.

Cartas-Espinel, Irene

Telechea-Fernandez, Marcelino

Manterola Delgado, Carlos

Avila Barrera, Andres

Saavedra Cuevas, Nicolas

Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review

WILEY PERIODICALS, INC

ESC HEART FAILURE

en

Aim Cancer treatments are associated with cardiotoxic events that predispose to cardiac pathology and compromise the survival of patients, making necessary the identification of new molecular biomarkers to detect cardiotoxicity. This scoping review aims to identify the available evidence on novel molecular biomarkers associated with cardiotoxicity in the adult population undergoing cancer therapy. Methods and results The databases Medline, Web of Science, Scopus, and Embase were screened for the identification of published studies until 23 August 2020, searching for novel molecular biomarkers reported in cancer therapy-related cardiac dysfunction in adult patients. A total of 42 studies that met the eligibility criteria were included. Fourteen studies reported 44 new protein biomarkers, 18 studies reported 57 new single nucleotide polymorphism biomarkers, and 11 studies reported 171 new gene expression profiles associated with cardiotoxicity. Data were extracted for 272 novel molecular biomarkers reported and evaluated in 7084 cancer patients, of which only 13 were identified in more than one study (MPO, sST2, GDF-15, TGF-B1, rs1056892, rs1883112, rs4673, rs13058338, rs1695, miR-1, miR-25-3p, miR-34a-5p, and miR-423-5p), showing values for area under the curve > 0.73 (range 0.74-0.85), odds ratio 0.26-7.17, and hazard ratio 1.28-1.80. Conclusions Multiple studies presented a significant number of novel molecular biomarkers as promising predictors for risk assessment of cardiac dysfunction related to cancer therapy, but the characteristics of the studies carried out and the determinations applied do not allow suggesting the clinical use of these molecular biomarkers in the assessment of cancer therapy-induced cardiotoxicity.

artículo de revisión

This work was supported by the Chilean ANID/Fondecyt-Postdoctorado No. 3180486 (A.L.R.-C), and Grants ANID/Doctorado Nacional No. 21150650 (I.C.-E.) and supported by the Universidad de La Frontera, project DI22-0014 (A.L.R.-C and I.C.-E.).

Este trabajo fue apoyado por la ANID/Fondecyt-Postdoctorado de Chile No. 3180486 (A.L.R.-C), y Becas ANID/Doctorado Nacional No. 21150650 (I.C.-E.) y apoyado por la Universidad de La Frontera, proyecto DI22-0014 ( A.L.R.-C e I.C.-E.).

10.1002/ehf2.13735

PDF

Cardiotoxicity

Molecular biomarkers

LVEF

CTRCD

Cancer therapy

Cardio-oncology/onco-cardiology

DOXORUBICIN-INDUCED CARDIOTOXICITY

GENOME-WIDE ASSOCIATION

T-CELL THERAPY

MULTIPLE BIOMARKERS

CARDIAC TOXICITY

HEART-FAILURE

POLYMORPHISM

MANAGEMENT

RISK

HER2

Sistemas cardíacos y cardiovasculares

Cardiotoxicidad

Biomarcadores moleculares

FEVI

CTRCD

Terapia contra el cáncer

Cardiooncología/oncocardiología

CARDIOTOXICIDAD INDUCIDA POR DOXORUBICINA

ASOCIACIÓN DE TODO EL GENOMA

TERAPIA DE CÉLULAS T

BIOMARCADORES MÚLTIPLES

TOXICIDAD CARDIACA

INSUFICIENCIA CARDÍACA

POLIMORFISMO

MANEJO

RIESGO

HER2

Oncología

Sistema Cardiovascular y Cardiaco

Biología Molecular

Novel molecular biomarkers of cancer therapy-induced cardiotoxicity in adult population: a scoping review

1651

1665

artículo de revisión

version publicada

CC BY-NC 4.0

CC BY-NC 4.0

acceso abierto

acceso abierto

ANID-FONDECYT 3180486

ANID-FONDECYT 21150650

UFRO DI22-0014

ANID FONDECYT 3180486

ANID FONDECYT 21150650

WOS:000766005500001